作者 | 哥吉拉 数据支持 | 勾股大数 据（www.gogudata.com） 5月29日，A股主要指数高开高走，截至收盘，沪指涨0.7%报3363点，深证成指涨1.24%，创业板指涨1.37%。全市场近4500股上涨，逾百 股涨停。 板块方面，金融科技、创新药、互联网、半导体等热门板块表现强势，市场情绪相比近日明显提振。 其中，创新药是涨幅最明显的板块之一，睿智医药、舒泰神、益方生物强势斩获20CM涨停，另有十多家医药股涨幅均超过10%，堪称又一轮 暴涨潮。 | 代码 | 名称 | 现价 | 1 9 mm a lond a rither more an a many 143 1994 (310 1 涨跌幅▼ | 年初至今涨跌幅 | 总市值1 | | --- | --- | --- | --- | --- | --- | | 300149 | 睿智医药 | 8.56 c | 20.06% | 33.33% | 43亿 | | 300204 | 舒泰神 | 23.04 c | 20.00% | 210.93% | 110亿 | | 688382 | 益元生物-U | 29.10 c | 20.00% | 11 ...

作者 | 黄绎达 编辑 | 郑怀舟 在A股市场，鲜有连续熊市超过三年的行业板块，而医药板块是其中的典型。从2021年7月到去年924行情启动之前，该板块经历了连续3年的下行调整， 申万医药生物指数在此期间的跌幅高达54%，板块市值近乎腰斩，众多医药龙头股亦同步陷入估值与业绩的双重回调。 在医药板块持续低迷的周期中，曾经风光无两的医药主题基金（以下简称：医药基金）也褪去了往日的光彩。根据wind统计，受医药板块长期熊市的拖 累，即便有去年924行情的提振，今年医药板块有所反弹，目前存续的600余只医药基金中，截至今年5月28日，大约2/3的基金净值目前还在1以下，最低 者甚至只有0.35。 但是从短期来看，进入2025年后，半数以上的医药基金在今年（截至5月28日）取得了正收益，表现优异者如长城医药产业精选、永赢医药创新智选、华 安医药生物、中银大健康等基金的同期收益在47%~56%区间，同类基金同期排名亦均位于前列，似乎医药基金的春天回来了。 那么，驱动医药基金在今年回暖的核心因素都有哪些？医药基金现在还能买吗？ 01 医药大盘反弹在beta层面支撑医药基金走强 医药基金近年来长期表现相对颓势，在不发生风格漂 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期： 2025年5月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 ...

Investment Rating - The report maintains a "Buy" rating for the company [6][7]. Core Views - The company achieved its first quarterly GAAP net profit in Q1 2025, with total revenue of $1.117 billion, a year-on-year increase of 49% [1][14]. - The company is expected to enter a significant period in 2025, with over 10 concept validation milestones anticipated [4]. - The sales of the key product, Zebutini, are expected to stabilize and grow throughout the year, despite a slight quarter-on-quarter decline in Q1 2025 [3][15]. Financial Performance - In Q1 2025, GAAP operating profit was $11.1 million, marking the first positive result, while adjusted operating profit was $139 million, a 195% year-on-year increase [1][2]. - The company reported a GAAP net profit of $1.27 million for the first time [1][14]. - The total revenue for Zebutini in Q1 2025 was $792 million, a 62% increase year-on-year, with U.S. sales reaching $563 million, also showing significant growth [3][15]. Cost Management - R&D expenses in Q1 2025 were $482 million, with a R&D expense ratio of 43%, down 18 percentage points year-on-year [2][34]. - Sales and management expenses were $459 million, with a corresponding expense ratio of 41%, down 16 percentage points year-on-year [2][34]. Future Outlook - The company forecasts revenues of $3.7517 billion, $4.5024 billion, and $5.4034 billion for 2025, 2026, and 2027 respectively, with net profits expected to be $703 million, $4.010 billion, and $6.744 billion in the same years [6][11]. - The company anticipates a GAAP operating profit for the full year 2025, with a gross margin expected to be in the range of 80%-90% [12][13].

Investment Rating - The report maintains a "Buy" rating for the company [6][7]. Core Views - The company achieved its first quarterly GAAP net profit in Q1 2025, with total revenue of $1.117 billion, a year-on-year increase of 49% [1][14]. - The company is expected to enter a significant period in 2025, with over 10 concept validation milestones anticipated [4]. - The sales of the key product, Zebutini, showed stable growth, with Q1 2025 revenue of $792 million, a 62% year-on-year increase [3][15]. Financial Performance - In Q1 2025, GAAP operating profit was $11.1 million, marking the first positive result, while adjusted operating profit was $139 million, up 195% year-on-year [1][2]. - The company reported a GAAP net profit of $1.27 million for the first time [1][14]. - The total revenue for 2025 is projected to be between $4.9 billion and $5.3 billion, with GAAP operating expenses estimated at $4.1 billion to $4.4 billion [12][13]. Cost Management - R&D expenses in Q1 2025 were $482 million, with a R&D expense ratio of 43%, down 18 percentage points year-on-year [2][34]. - Sales and management expenses were $459 million, with a corresponding expense ratio of 41%, down 16 percentage points year-on-year [2][28]. Product Performance - Zebutini's revenue in the U.S. was $563 million, a year-on-year increase of over 60%, while European sales reached $116 million, up 73% [3][15]. - The other significant product, Trelizumab, generated $171 million in revenue in Q1 2025, reflecting an 18% year-on-year increase [3][23]. Future Outlook - The company expects to achieve a positive GAAP operating profit for the full year 2025, with a projected gross margin between 80% and 90% [12][13]. - The forecasted revenue for 2025-2027 is $37.52 billion, $45.02 billion, and $54.03 billion, respectively [6].

Core Insights - The approval of multiple BTK inhibitors in China is transforming the treatment landscape for Chronic Lymphocytic Leukemia (CLL) and B-cell lymphomas, with a notable shift towards second-generation BTK inhibitors [1][3][4] Group 1: Market Overview - As of now, five BTK inhibitors have been approved in China, including three imported drugs and two domestic drugs, with the first-generation inhibitor ibrutinib and three second-generation inhibitors [3] - The global incidence of CLL is significant, with 191,000 new cases and 61,000 deaths annually, primarily affecting elderly patients with a median age of 65 in China [2] Group 2: Treatment Efficacy and Safety - The five-year survival rate for CLL patients is high, ranging from 80% to 90%, with low-risk patients having a median survival of nearly 20 years [2] - Newer BTK inhibitors demonstrate improved safety profiles compared to first-generation inhibitors, which have seen a decline in global recommendation levels due to safety concerns [3][4] Group 3: Future Directions - The development of BCL2 inhibitors is underway, with ongoing clinical trials combining these with BTK inhibitors, indicating a potential new direction for CLL treatment [5] - The increasing elderly population in China presents challenges for long-term management of CLL patients, necessitating systematic approaches to address treatment adherence and adverse effects [5]

Group 1 - The establishment of the Business and Medical Affairs Advisory Committee aims to assist the board in overseeing the company's business activities and providing strategic advice on business factors [1] - The committee is required to regularly review and reassess its charter and submit any proposed changes to the board for approval [2] - The committee has the authority to request the attendance of any senior officer, employee, or external legal advisor at its meetings [3] Group 2 - The committee can invite directors and other individuals to attend its meetings at the discretion of the committee chair [4] - The board may appoint a committee chair at its discretion [5] - The committee is responsible for reviewing business strategies and plans, as well as medical affairs strategies and plans, and discussing reports from management [6] Group 3 - The committee assists the board and the compensation committee in developing and evaluating performance goals related to business and medical affairs incentive compensation plans [6] - The committee has the authority to access all company records and may establish subcommittees as deemed appropriate [6] - The committee can hire legal, consulting, and other advisors to assist in fulfilling its responsibilities [6]

Group 1 - The establishment of the Scientific Advisory Committee aims to assist the Board in overseeing the company's R&D activities and providing strategic scientific advice [1] - The committee must have at least two members, appointed by the Board, who will consider the scientific, clinical development, regulatory, medical, and technical expertise of the directors [1][2] - The committee has the authority to review and assist the Board in handling other matters and must report its activities and recommendations regularly to the Board [3] Group 2 - The committee is responsible for reviewing the appropriateness of its charter and submitting any proposed changes to the Board for approval [2] - The committee will receive reports from management regarding the company's R&D plans and discuss them [2] - The committee may assist the Board and the Compensation Committee in developing and evaluating any research or development performance targets under the company's incentive compensation plans [2][4] Group 3 - The committee has the right to access all company records and may invite senior officers or external legal advisors to attend meetings [3] - The committee can establish subcommittees as deemed appropriate and may hire legal, consulting, and other advisors to assist in fulfilling its responsibilities [3][4] - The committee is tasked with evaluating the capabilities and performance of key scientific personnel and the depth and breadth of the company's scientific resources [4]

BEONE MEDICINES LTD. 百濟神州有限公司 提名及企業管治委員會章程 I. 一般成立目標聲明 A. 成員 提名委員會應每年審閱及重新評估本章程的恰當性，並將任何建議變動 提交董事會批准。 提名委員會應定期就企業管治的法律及實務的重大發展向董事會提供意 見，並在提名委員會認為適當的情況下就企業管治事宜向董事會提出建 議。提名委員會應制定企業管治框架，並向董事會提出建議並就此進行 監督，包括定期審查和重新評估本公司的章程、組織法規、企業管治 指引和行為守則的充分性，該等文件應滿足納斯達克股票市場規則第 B. 董事會和委員會的年度績效評估 提名委員會應每年評估其績效並將向董事會報告評估結果。 C. 挑選新董事 根據納斯達克股票市場規則第5605(e)(1)(B)條，本公司的提名委員會將 會完全由符合納斯達克股票市場規則第5605(e)(1)(B)條的獨立性測試的 董事組成。提名委員會成員的董事人數由董事會不時決定，但至少由兩 名董事組成。董事會應指定提名委員會的一名成員擔任提名委員會主席。 B. 免職和替換 提名委員會的成員應每年由董事會任命，並可在提出因由或並無提出因 由的情況下隨時由董事會決定替 ...

Core Points - The Audit Committee of BeiGene, Ltd. is established to oversee the quality and integrity of the company's accounting and financial reporting processes, as well as compliance with legal and regulatory requirements [3][6][15] - The committee must consist of at least three members, all of whom must be independent directors according to NASDAQ rules [1][4] - The committee is responsible for appointing, retaining, and terminating the independent auditor, as well as approving all audit services and their terms [7][9][10] Membership and Appointment - The Audit Committee must have members who can read and understand basic financial statements, with at least one member possessing relevant financial or accounting experience [1][2] - The Nominating and Corporate Governance Committee is responsible for recommending candidates for the Audit Committee [1][5] Meetings and Procedures - The Audit Committee is required to meet at least quarterly and can convene via teleconference or other communication devices [2][5] - The agenda for each meeting is to be prepared in consultation with the committee chair and management [2][6] Responsibilities and Powers - The committee is tasked with reviewing and assessing the adequacy of its charter annually and reporting its findings to the board [6][9] - It must evaluate the qualifications, performance, and independence of the independent auditor and report its conclusions to the board [9][10] - The committee is authorized to hire external advisors, including legal counsel, to assist in fulfilling its responsibilities [15][19] Financial Reporting Oversight - The Audit Committee must review significant financial reporting issues and judgments made in the preparation of financial statements [11][12] - It is responsible for discussing the company's quarterly financial reports with management and the independent auditor before submission [13][14] Risk Management - The committee is required to discuss the guidelines and policies governing the company's assessment and management of financial risks [14][19] - It must establish procedures for handling complaints regarding accounting, internal controls, or auditing matters [14][19]